论文部分内容阅读
目的探讨IL-18抗体(IL-18Ab)对小鼠阿霉素肾病的治疗作用及机制。方法 30只雄性昆明种小鼠,随机分为3组,模型组及治疗组以阿霉素(ADR)尾静脉注射建立小鼠类似人类微小病变肾病模型,尿液做24 h尿蛋白定量测定。实验第42天处死小鼠,检测血生化指标,并观察肾组织病理改变。结果 IL-18Ab治疗组与模型组比较尿蛋白明显减少,血脂降低,肾脏病理损害减轻。结论 IL-18Ab能降低ADR小鼠尿蛋白排泄量,改善高脂血症、低蛋白血症,减轻肾小球上皮细胞足突的损伤。
Objective To investigate the therapeutic effect and mechanism of IL-18 antibody (IL-18Ab) on doxorubicin-induced nephropathy in mice. Methods Thirty male Kunming mice were randomly divided into three groups. The model mice and the treatment group were injected with doxorubicin (ADR) into the caudal vein to establish a mouse model of human minimal lesion nephropathy. The urinary protein was measured 24 h urinary protein. Mice were sacrificed on the 42nd day of the experiment, blood biochemical markers were detected, and renal pathological changes were observed. Results Compared with the model group, the urinary protein was significantly decreased, the blood lipids decreased, and the renal pathological damage was alleviated in the IL-18Ab treatment group. Conclusion IL-18Ab can reduce urinary protein excretion, improve hyperlipidemia, hypoalbuminemia and alleviate glomerulus foot process in ADR mice.